Back to news

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

Globe Newswire•10/08/2026•03:30 ET
0
Whiz Insights

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in